Medpace Holdings (MEDP) director McCarthy sells 1,140 shares at $605.37

Rhea-AI Filing Summary

Medpace Holdings, Inc. director Cornelius P. McCarthy III reported a sale of 1,140 shares of common stock on 2026-08-11 in a transaction coded as a sale in an open market or private transaction at $605.37 per share. Following this sale, his directly held position stands at 12,275 shares. The filing does not indicate that the transaction was made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 1,140 shares

Net Sell 1 txn

Insider McCarthy Cornelius P. III

Role Director

Sold 1,140 shs ($690K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,140	$605.37	$690K

Holdings After Transaction: Common Stock — 12,275 shares (Direct)

Key Figures

Shares sold: 1,140 shares Sale price per share: $605.37 Shares held after sale: 12,275 shares +1 more

4 metrics

Shares sold 1,140 shares Common stock sale reported on 2026-08-11

Sale price per share $605.37 Price per share for the 1,140 common shares sold

Shares held after sale 12,275 shares Direct common stock holdings following the reported transaction

Net insider share change 1,140 shares Net-sell activity in the transaction summary

Key Terms

Form 4, open market or private transaction, Rule 10b5-1 trading plan

3 terms

Form 4 regulatory

"reported on this Form 4 insider trading report"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open market or private transaction financial

"transaction coded as a sale in an open market or private transaction"

Rule 10b5-1 trading plan regulatory

"not indicated as made under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

What insider transaction did Medpace Holdings (MEDP) report on this Form 4?

Medpace Holdings reported that director Cornelius P. McCarthy III sold 1,140 shares of common stock on 2026-08-11 in a transaction coded as a sale in an open market or private transaction.

At what price were the MEDP shares sold by Cornelius P. McCarthy III?

The reported sale by Cornelius P. McCarthy III was executed at a price of $605.37 per share, as disclosed for the 1,140 shares of Medpace Holdings common stock sold.

How many Medpace (MEDP) shares does Cornelius P. McCarthy III hold after this sale?

After the reported transaction, Cornelius P. McCarthy III directly holds 12,275 shares of Medpace Holdings common stock, as stated in the Form 4’s post-transaction holdings field.

Was the Medpace (MEDP) insider sale made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not checked, and no footnote describes a trading plan, indicating the reported sale was not affirmed as made under a Rule 10b5-1 plan.

What is the net share impact of the reported Medpace (MEDP) insider trade?

The Form 4 shows a net disposition of 1,140 shares, all from a single sale transaction, resulting in net-sell activity as summarized in the filing’s transaction summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 04:13 PM Accepted by SEC EDGAR 08/13/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCarthy Cornelius P. III

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OHIO 45227

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2026		S		1,140	D	$605.37	12,275	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Cornelius P. McCarthy III	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)